La catena delle opzioni mostra i dati chiave delle opzioni azionarie di IN8bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per IN8bio..

IN8bio (NASDAQ:INAB) Azioni, Catena delle Opzioni

IN8BIO INC

IN8bio

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

IN8bio Inc

INABA DENKISANGYO CO LTD by Inaba Denkisangyo Co., Ltd.

Inaba Denkisangyo Co Ltd

INABA SEISAKUSHO CO LTD by INABA SEISAKUSHO CO LTD.

Inaba Seisakusho Co Ltd

Inabata & Co Ltd

News

Press Releases

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Health Care

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Earnings

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Analyst Ratings

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

General

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

INAB

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Entero Therapeutics

Ernexa Therapeutics

Evogene

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

HCW Biologics

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

OSR Holdings

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Comments

IN8bio

IN8bio (INAB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO